Kai Kupferschmidt, Gretchen VogelScience’s COVID-19 reporting is supported by the Heising-Simons Foundation.In the tumultuous rollout of AstraZeneca's COVID-19 vaccine, all eyes were on the United States this week, where the company had a highly public communication breakdown over the vaccine's efficacy with an expert panel overseeing a large study in the Americas.
But on the other side of the Atlantic, the vaccine faces new concerns about safety as an explanation gains ground for the unusual strokes and clotting disorders recorded in at least 30 recipients.Now, a group of researchers led by German clotting specialist Andreas Greinacher of the University of Greifswald says the highly unusual combination of symptoms—widespread blood clots.